牛牛AI助理已提取核心訊息
Mikael Dolsten, President of R&D at Pfizer Inc, was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report did not provide information on the number of shares held by Dolsten after the action. As this information is crucial for investors, the lack of details might affect their ability to make fully informed decisions regarding their investments in Pfizer.
Mikael Dolsten, President of R&D at Pfizer Inc, was reported to have engaged in a transaction involving the company's stock on February 27, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report did not provide information on the number of shares held by Dolsten after the action. As this information is crucial for investors, the lack of details might affect their ability to make fully informed decisions regarding their investments in Pfizer.
據報道，輝瑞公司研發總裁米凱爾·多爾斯滕於2024年2月27日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。該報告沒有提供有關Dolsten在行動後持有的股票數量的信息。由於這些信息對投資者至關重要，因此缺乏細節可能會影響他們就輝瑞的投資做出完全明智的決策的能力。
據報道，輝瑞公司研發總裁米凱爾·多爾斯滕於2024年2月27日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。該報告沒有提供有關Dolsten在行動後持有的股票數量的信息。由於這些信息對投資者至關重要，因此缺乏細節可能會影響他們就輝瑞的投資做出完全明智的決策的能力。
有用
沒用